Tumor Biology

, Volume 36, Issue 4, pp 2863–2868 | Cite as

Different frequencies and effects of ABCB1 T3435C polymorphism on clinical and laboratory features of B cell chronic lymphocytic leukemia in Kurdish patients

Research Article


Finding the effects of gene polymorphism on cancer pathogenesis is very desirable. The ATP-binding cassette is involved in drug metabolism, and the polymorphism of this gene may be an important risk factor in B cell chronic lymphocytic leukemia (B-CLL) or progression and/or response to chemotherapy agents. For the first time, the present study was aimed to evaluate the probable effects of ABCB1 T3435C polymorphism on clinical and laboratory features of Kurdish patients with B-CLL. This descriptive analytical case-control study was performed on 50 B-CLL patients and 100 healthy subjects. Serum levels of beta-2-microglobulin (B2M) and lactate dehydrogenase (LDH) and blood WBC, RBC, Plt and ESR were measured. The T3435C polymorphism of the ABCB1 gene was determined by PCR-RFLP. Concentration of serum and blood markers was significantly higher in the malignant group than in the benign subjects. The CC genotype had the highest frequency (66 %) in the patient groups. There are no significant differences between the genotypes and type of treatment. Our results demonstrate the high frequency of C allele of ABCB1 T3435C in B-CLL patients with Kurdish ethnicity. We also show that this polymorphism has a significant risk factor in B-CLL. However, the effect of this polymorphism on clinical and laboratory characteristics of B-CLL patients was not significant.


B-CLL ABCB1 T3435C polymorphism Chemotherapy agents B2M 



The authors wish to thank all patients and health staff who participated in this study. This work has no financially support.

Conflicts of interest



  1. 1.
    Hamblin TJ. Achieving optimal outcomes in chronic lymphocytic leukaemia. Drugs. 2001;61(5):593–611.CrossRefPubMedGoogle Scholar
  2. 2.
    Gill S, Carney D, Ritchie D, Wolf M, Westerman D, Prince HM, et al. The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Ann Oncol. 2010;21(2):331–4.CrossRefPubMedGoogle Scholar
  3. 3.
    Houlston RS, Catovsky D, Yuille MR. Genetic susceptibility to chronic lymphocytic leukemia. Leuk. 2002;16(6):1008–14.CrossRefGoogle Scholar
  4. 4.
    Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Zent CS, Call TG, Hogan WJ, Shanafelt TD, Kay NE. Update on risk-stratified management for chronic lymphocytic leukemia. Leuk Lymphoma. 2006;47(9):1738–46.CrossRefPubMedGoogle Scholar
  6. 6.
    Breier A, Barancik M, Sulova Z, Uhrik B. P-glycoprotein—implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets. 2005;5(6):457–68.CrossRefPubMedGoogle Scholar
  7. 7.
    Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut. 2003;52(5):759–66.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Zintzaras E. Is there evidence to claim or deny association between variants of the multidrug resistance gene (MDR1 or ABCB1) and inflammatory bowel disease? Inflamm Bowel Dis. 2012;18(3):562–72.CrossRefPubMedGoogle Scholar
  9. 9.
    Friedenberg WR, Spencer SK, Musser C, Hogan TF, Rodvold KA, Rushing DA, et al. Multi-drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma. 1999;34(1–2):171–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Rosenwald A. Multi-drug resistance in B-cell chronic lymphocytic leukemia (B-CLL): a feature of B-CLL sub-sets with poor prognosis genetic alterations? Leuk Lymphoma. 2006;47(11):2263–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Sparrow RL, Hall FJ, Siregar H, Van der Weyden MB. Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance. Leuk Res. 1993;17(11):941–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Webb M, Brun M, McNiven M, Le Couteur D, Craft P. MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders. Br J Haematol. 1998;102(3):710–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol. 2002;119(4):976–84.CrossRefPubMedGoogle Scholar
  14. 14.
    Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98(8):2319–25.CrossRefPubMedGoogle Scholar
  15. 15.
    Robak T, Blonski JZ, Kasznicki M, Gora-Tybor I, Dwilewicz-Trojaczek J, Boguradzki P, et al. Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Leuk. 2001;15(10):1510–6.CrossRefGoogle Scholar
  16. 16.
    Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003;97(7):1711–20.CrossRefPubMedGoogle Scholar
  17. 17.
    Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenet. 2001;11(3):217–21.CrossRefGoogle Scholar
  18. 18.
    Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97(7):3473–8.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70(2):189–99.CrossRefPubMedGoogle Scholar
  20. 20.
    Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219–34.PubMedGoogle Scholar
  21. 21.
    Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood. 2006;107(3):859–61.CrossRefPubMedGoogle Scholar
  22. 22.
    Hoellein A, Decker T, Bogner C, Oelsner M, Hauswald S, Peschel C, et al. Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70 status. J Cancer Res Clin Oncol. 2010;136(3):403–10.CrossRefPubMedGoogle Scholar
  23. 23.
    Penna G, Allegra A, Alonci A, Aguennouz M, Garufi A, Cannavo A, et al. MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis. Med Oncol (Northwood Lond Engl). 2011;28(4):1549–54.CrossRefGoogle Scholar
  24. 24.
    Goreva OB, Grishanova AY, Mukhin OV, Domnikova NP, Lyakhovich VV. Possible prediction of the efficiency of chemotherapy in patients with lymphoproliferative diseases based on MDR1 gene G2677T and C3435T polymorphisms. Bull Exp Biol Med. 2003;136(2):183–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Jamroziak K, Balcerczak E, Calka K, Piaskowski S, Urbanska-Rys H, Salagacka A, et al. Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leuk Res. 2009;33(2):332–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Rochlitz CF, de Kant E, Neubauer A, Heide I, Bohmer R, Oertel J, et al. PCR-determined expression of the MDR1 gene in chronic lymphocytic leukemia. Ann Hematol. 1992;65(6):241–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Li YH, Wang YH, Li Y, Yang L. MDR1 gene polymorphisms and clinical relevance. Yi chuan xue bao = Acta genetica Sinica. 2006;33(2):93–104.PubMedGoogle Scholar
  28. 28.
    Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol. 2003;14(7):1889–96.CrossRefPubMedGoogle Scholar
  29. 29.
    Bernal ML, Sinues B, Fanlo A, Mayayo E. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther Drug Monit. 2003;25(1):107–11.CrossRefPubMedGoogle Scholar
  30. 30.
    Jamroziak K, Balcerczak E, Mlynarski W, Mirowski M, Robak T. Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDR1 gene in a sample of Polish population. Pol J Pharmacol. 2002;54(5):495–500.PubMedGoogle Scholar
  31. 31.
    Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterol. 2003;124(1):26–33.CrossRefGoogle Scholar
  32. 32.
    Balram C, Sharma A, Sivathasan C, Lee EJ. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br J Clin Pharmacol. 2003;56(1):78–83.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001;18(10):1400–4.CrossRefPubMedGoogle Scholar
  34. 34.
    Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci. 2000;25(1):1–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Mizutani T, Masuda M, Nakai E, Furumiya K, Togawa H, Nakamura Y, et al. Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab. 2008;9(2):167–74.CrossRefPubMedGoogle Scholar
  36. 36.
    Rund D, Azar I, Shperling O. A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease. Adv Exp Med Biol. 1999;457:71–5.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Biochemistry, College of Science, Kurdistan Science and Research BranchIslamic Azad UniversitySanandajIran
  2. 2.Department of Biology, College of ScienceIslamic Azad UniversitySanandajIran
  3. 3.Department of Epidemiology and Biostatistics, Faculty of MedicineKurdistan University of Medical SciencesSanandajIran
  4. 4.Department of Internal Medicine, Faculty of MedicineKurdistan University of Medical SciencesSanandajIran
  5. 5.Cellular and Molecular Research Center, Faculty of MedicineKurdistan University of Medical SciencesSanandajIran
  6. 6.Department of Clinical Biochemistry, Faculty of MedicineKurdistan University of Medical SciencesSanandajIran
  7. 7.Division of Hematology-OncologyTohid HospitalSanandajIran

Personalised recommendations